Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California. Show more
Location: 3940 Trust Way, Hayward, CA, 94545, United States | Website: https://benitec.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
361.7M
52 Wk Range
$9.10 - $17.15
Previous Close
$13.78
Open
$13.83
Volume
481,169
Day Range
$13.63 - $14.36
Enterprise Value
263.3M
Cash
97.74M
Avg Qtr Burn
-5.897M
Insider Ownership
3.12%
Institutional Own.
91.06%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BB-301 Details Oculopharyngeal Muscular Dystrophy | Phase 1/2 Data readout |